
    
      To observe objective response rate (ORR) of apatinib in RET fusion positive pre-treated
      advanced NSCLC.

      To observe Progression free survival （PFS）. To assess the overall survival (OS). To assess
      safety and tolerability. To evaluate quality of life. To explore the relationship between
      biomarkers and the toxicity/efficacy of apatinib.
    
  